Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million.
PacBio alleged in its suit that Oxford Nanopore is infringing on a patent it holds related to single-molecule nanopore sequencing.
PacBio recently launched a new sequencing chemistry for Sequel that increases read lengths, and plans to double the platform's throughput by the end of the year.
Pacific Biosciences nearly doubled its product and services revenue due to sales of its Sequel instrument.
Roche said the timeline to launch a diagnostic system and assays based on PacBio's technology would be too long; instead, it will focus on commercializing Genia's technology.
The two companies struck a $75 million deal in 2013 to launch a sequencing system and assays for the diagnostic market.
PacBio's product revenues increased due to sales of its Sequel system. The company also alleged that Oxford Nanopore's products infringe on a patent it holds.
The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.
The researchers have generated the most contiguous de novo assembly of a human genome to date and plan to use it as a reference for population sequencing projects.
During a live webcast, CTO Clive Brown provided an update on the company's development plans and upcoming updates.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.